Loading
institutionsInstitution
Jilin Cancer Hospital
Jilin Cancer Hospital in Changchun is the centre that led China's small cell lung cancer immunotherapy trials, including ASTRUM-005 and CAPSTONE-1.
Also called: 吉林省肿瘤医院
Overview
Provincial cancer centre whose thoracic oncology department under Cheng Ying has been principal investigator for serplulimab (ASTRUM-005), adebrelimab (CAPSTONE-1), benmelstobart plus anlotinib and other extensive-stage SCLC trials, making a north-eastern provincial hospital one of the most cited sites in the disease.
Location
Changchun, CN
Type
cancer center
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#440 · 10 points (0 Newsweek + 0 NCI + 10 from 5 linked objects) · ranking
- Small cell lung cancer trials
- Thoracic oncology
Similar pages
- CompanyShanghai Henlius Biotech
Shares ASTRUM-005, Serplulimab, Small-cell lung cancer and the tag china.
- TreatmentAnlotinib
Shares Ying Cheng, Small-cell lung cancer and the tag china.
- CompanyJiangsu Hengrui Pharmaceuticals
Shares CAPSTONE-1, Adebrelimab, Small-cell lung cancer and the tag china.
- TreatmentBenmelstobart
Shares Small-cell lung cancer and the tag china.
- TrialA Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors
Shares Serplulimab, Small-cell lung cancer.
- TrialA Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
Shares Serplulimab, Small-cell lung cancer.
- TrialA Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC
Shares Serplulimab, Small-cell lung cancer.
- TrialTo Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
Shares Serplulimab, Small-cell lung cancer.
cancers
drugs
ApprovedMonoclonal antibody (anti-PD-L1, humanised IgG4)
Adebrelimab · Arelili
ApprovedMonoclonal antibody (anti-PD-1)
Serplulimab · Hansizhuang / Hetronifly